GlassScriptPhysician profile
Beau C Jennings
NPI 1275568115
$9,399.53
in general payments reported to CMS, 2019-2025
41 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $476 · 2021: $187 · 2022: $1,549 · 2023: $2,062 · 2024: $1,727 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,475.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,735.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $949.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $824.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $721.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $696.54 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $604.47 | 2022-2025 | |
| Abbvie INC. | $473.07 | 2022-2025 | |
| Abbott Laboratories | $400.63 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $362.44 | 2019-2023 | Belsomra, Steglatro |
| Corium, LLC | $340.38 | 2023-2025 | Azstarys |
| Astellas Pharma US INC | $275.96 | 2019-2025 | Veozah |
| Amgen INC. | $242.02 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $188.54 | 2020-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.92 | 2022-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $177.96 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beau Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.